|
4A: Significant correlations with ESA use
|
|---|
| |
All patients
|
Patients with ESA use
|
Patients without ESA use
|
Unadjusted OR (95%CI)
|
*p-value
|
Adjusted OR (95% CI)
|
**Corrected p value
|
|---|
|
N = 290 (%)
|
N = 70 (24.2%)
|
N = 219 (75.8%)
|
|---|
|
ABCC1 rs2074087
|
GG 215 (74.4)
|
46 (65.7)
|
169 (77.2)
|
1.78 (1.03- 3.08)
|
0.054
|
2.09 (1.18 - 3.68)
|
0.011
|
|
GC 69 (23.9)
|
22 (31.4)
|
47 (21.5)
| |
|
CC 5 (1.7)
|
2 (2.8)
|
3 (1.4)
| |
|
4B: Significant correlations with CSF use
|
| |
All patients
|
Patients with CSF use
|
Patients without CSF use
|
Unadjusted OR
|
*p-value
|
Adjusted OR
|
**Corrected p value
|
|
N = 290 (%)
|
N = 62 (21.4%)
|
N = 228 (78.6%)
|
(95%CI)
|
(95% CI)
|
|
ABCC2 rs2073337
|
AA 101 (34.8)
|
27 (43.5)
|
74 (32.5)
|
0.61 (0.39- 0.96)
|
0.031
|
0.60 (0.37-0.99)
|
0.039
|
|
AG 148 (51.0)
|
31 (50.0)
|
117 (51.3)
|
|
GG 41 (14.1)
|
4 (6.5)
|
37 (16.2)
|
|
GSTP1 rs1695
|
AA 121 (41.7)
|
33 (53.2)
|
88 (38.6)
|
0.54 (0.34; 0.86)
|
0.010
|
0.55 (0.33-0.90)
|
0.017
|
|
AG 137 (47.2)
|
27 (43.5)
|
110 (48.2)
|
|
GG 32 (11.0)
|
2 (3.2)
|
30 (13.2)
|
|
ERCC2 Rs1799793
|
GG 136 (48.2)
|
21 (33.9)
|
115 (50.4)
|
0.67 (0.45- 1.00)
|
0.048
|
0.63 (0.41-0.98)
|
0.042
|
|
GA 111 (39.4)
|
30 (48.4)
|
81 (35.5)
|
|
AA 35 (12.4)
|
9 (14.5)
|
26 (11.4)
|
- OR: Odds Ratio using wild type as reference category. *Uncorrected p values were calculated using binary logistic regression for the need for ESA/CSF use without correction for covariates. Per-allele ORs and 95% CIs are shown. There were missing genotypes for rs2074087 (n = 1), rs1799793 (n = 8). **Corrected p values were obtained using a logistic regression for the need for ESA/CSF use while including the following covariates: genetic variants, age, BMI, dosage of carboplatin (AUC) and number of administered cycles.
